A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication

We present a case with decreased metabolic activity of CYP2D6, a cytochrome P450 enzyme catalyzing the metabolism of nortriptyline (NT). Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype C...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2004, 19(5), , pp.750-752
Main Authors: Lee, Soo-Youn, Ki, Chang-Seok, Hong, Kyung Sue, Kim, Jong Won
Format: Article
Language:English
Subjects:
Antidepressive Agents, Tricyclic - adverse effects
Antidepressive Agents, Tricyclic - pharmacokinetics
Case Report
Cytochrome P-450 CYP2D6 - genetics
Cytochrome P-450 CYP2D6 - metabolism
Depression - drug therapy
Depression - genetics
Genotype
Humans
Male
Middle Aged
Nortriptyline - adverse effects
Nortriptyline - pharmacokinetics
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present a case with decreased metabolic activity of CYP2D6, a cytochrome P450 enzyme catalyzing the metabolism of nortriptyline (NT). Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B. This case suggests the clinical usefulness of pharmacogenetic testing in individualized dosage adjustments of NT.
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2004.19.5.750